This research study is testing Letermovir to see how well it prevents cytomegalovirus (CMV) infections from returning in solid organ transplant recipients (people who have received a heart, kidney, or liver transplant). You may be able to join if you are an adult (18-75 years old) who has recently been treated for CMV disease after your transplant and your doctor believes you need further protection. The study aims to see how many people experience a CMV relapse within six months after starting Letermovir. The study is currently unclear about its recruitment status and plans to enroll about 25 participants.

Study design

This is an open-label study, meaning both you and your doctors will know you are receiving Letermovir. Approximately 25 participants will receive Letermovir.

What's involved

You would take Letermovir 480 mg by mouth once a day for 60 days. Blood tests for CMV-specific T cells will be done at the start and end of this treatment.

Compensation

Not stated in the trial record.

Follow-up

You will be followed for four months after stopping Letermovir to check for CMV relapse, with the primary outcome measured at six months after starting the intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.